(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
In a positive move, last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Eisai Co., Ltd (OTC: ESALY) and Biogen’s ...
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...
The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...
Biogen’s investors are growing restless. Wednesday’s third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year ...
Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback